Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
The Axcelis Technologies Inc (ACLS) news page on Stock Titan aggregates company announcements, industry event participation and regulatory disclosures focused on its role in the semiconductor equipment market. Axcelis describes itself as a leading supplier of enabling ion implantation solutions for the semiconductor industry, with more than 45 years of experience providing high-productivity systems and lifecycle support.
Investors and industry followers can use this page to monitor Axcelis’ updates on product launches, technology platforms and market engagement. Recent news has highlighted the introduction of the Purion Power Series+ ion implant platform for next generation power devices, including silicon carbide (SiC) power devices and superjunction architectures, as well as the GSD Ovation ES high current implanter for engineered substrates. Company releases also cover its participation in major industry events such as SEMICON Japan and the International Conference on Silicon Carbide and Related Materials (ICSCRM), where Axcelis technologists present technical work on SiC and related materials.
The feed also includes financial and corporate developments, such as quarterly results announcements, conference call schedules and Axcelis’ participation in investor conferences. A significant recent development is the all-stock merger agreement with Veeco Instruments Inc., under which Veeco is expected to become a wholly owned subsidiary of Axcelis, subject to regulatory and shareholder approvals.
By following this ACLS news page, readers can track Axcelis’ communications on its ion implantation product portfolio, aftermarket strategy, global customer engagement and planned combination with Veeco, all drawn from official press releases and SEC-referenced materials.
Axcelis Technologies (Nasdaq: ACLS) updated its fourth quarter 2020 financial guidance, expecting revenue of approximately $120 million, exceeding previous guidance of $110 million. Gross margin is projected at 43%, improved from 41%, with earnings per share rising to $0.32 from $0.21. The company also announced a $100 million share repurchase program for 2021, indicating strong confidence in operational prospects. Upcoming financial results will be disclosed on February 10, 2021, with a conference call scheduled for February 11, 2021.
Axcelis Technologies (Nasdaq: ACLS) announced its participation in the 23rd Annual Needham Virtual Growth Conference from January 11-15, 2021. Key executives including President and CEO Mary Puma, CFO Kevin Brewer, and EVP Doug Lawson will engage in a fireside chat on January 13 at 11:30 a.m. EST. The event will include one-on-one meetings and a live webcast accessible on their website. Axcelis, based in Beverly, Mass., specializes in ion implantation solutions for the semiconductor industry, boasting over 40 years of experience.
Axcelis Technologies (Nasdaq: ACLS) will participate in the 12th Annual CEO Investor Summit on December 16, 2020. Key executives, including Mary Puma, Kevin Brewer, and Doug Lawson, will engage in a virtual format with investors and analysts. This event allows for up to six meetings per company, and a pre-recorded company overview will be available for viewing 24 hours prior. Registration is required by December 10, 2020 to ensure participation in this exclusive event.
Axcelis Technologies (NASDAQ: ACLS) will participate in the virtual D.A. Davidson Semicap, Laser and Optical Conference on December 15, 2020. The management team will hold one-on-one meetings throughout the event. With over 40 years of experience, Axcelis supplies innovative ion implantation solutions critical to the semiconductor industry's manufacturing process.
Axcelis Technologies (ACLS) reported third-quarter 2020 revenue of $110.4 million, down from $123 million in Q2 2020. Operating profit decreased to $13.9 million, while net income was $10.8 million or $0.32 per diluted share, compared to $13.3 million or $0.39 per diluted share in the previous quarter. Gross margin improved to 43.6%. Cash and equivalents rose to $212.7 million. For Q4, revenue is projected to be around $110 million with a 41% gross margin and earnings per share of $0.21.
Axcelis Technologies (Nasdaq: ACLS), based in Beverly, Mass., is set to participate in the Benchmark Technology Conference on November 12th, 2020. The conference will be conducted virtually, featuring one-on-one meetings hosted by Doug Lawson, the executive vice president of corporate marketing and strategy. Investors interested in attending can get more details and schedule meetings through the Benchmark website.
With over 40 years in the industry, Axcelis specializes in ion implantation solutions crucial for semiconductor manufacturing.
Axcelis Technologies announced the shipment of multiple Purion VXE and Purion EXE high energy systems to major CMOS image sensor manufacturers. These systems, part of the Purion high energy implanter series, support advanced applications in the growing IoT and mobile markets. Bill Bintz, Executive Vice President, emphasized the demand for these high energy implants, which offer precise doping profiles. This development further strengthens Axcelis' leadership position in the semiconductor industry, showcasing a robust product portfolio designed to meet customer needs.
Axcelis Technologies (ACLS) will announce its third quarter 2020 financial results on November 5, 2020, at 4:00 p.m. ET. Following the release, a conference call will be held on November 6, 2020, at 8:30 a.m. ET, accessible via audio webcast on Axcelis' investor page. Participants can ask questions by dialing 866.588.8911 (or 707.294.1561 internationally) with Conference ID: 1999553. Axcelis has been innovating in the semiconductor industry for over 40 years, focusing on ion implantation systems.
Axcelis Technologies (Nasdaq: ACLS) announced the shipment of its first Purion H200 high current implanter evaluation system and a follow-on order for the Purion M SiC medium current implanter to leading power device manufacturers. The Purion H200 is designed for Si power device production, while the Purion M SiC system supports fab capacity expansion. Both systems were shipped in Q3 2020. CEO Mary Puma emphasized the importance of expanding their customer footprint in the power device market to achieve the company's long-term $650M business model.
On September 16, 2020, Axcelis Technologies (Nasdaq: ACLS) announced the shipment of multiple evaluation systems for its next-generation Purion H to customers in the Asia Pacific region. This shipment, part of their third-quarter activities, is aimed at advanced logic and 3D NAND memory device manufacturers. CEO Mary Puma highlighted the significance of these shipments for growth in the high current ion implant market, projecting a long-term business model worth $650M. The Purion H platform features advanced technology designed to meet critical manufacturing challenges.
FAQ
What is the current stock price of Axcelis Tech Ord (ACLS)?
What is the market cap of Axcelis Tech Ord (ACLS)?
